ATE319742T1 - Verbesserte zyclische crf agonisten - Google Patents
Verbesserte zyclische crf agonistenInfo
- Publication number
- ATE319742T1 ATE319742T1 AT95943747T AT95943747T ATE319742T1 AT E319742 T1 ATE319742 T1 AT E319742T1 AT 95943747 T AT95943747 T AT 95943747T AT 95943747 T AT95943747 T AT 95943747T AT E319742 T1 ATE319742 T1 AT E319742T1
- Authority
- AT
- Austria
- Prior art keywords
- nle21
- phe12
- rcrf
- cyclo
- cys
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5751—Corticotropin releasing factor [CRF] (Urotensin)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/353,928 US5663292A (en) | 1994-12-12 | 1994-12-12 | Cyclic CRF analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE319742T1 true ATE319742T1 (de) | 2006-03-15 |
Family
ID=23391187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95943747T ATE319742T1 (de) | 1994-12-12 | 1995-12-12 | Verbesserte zyclische crf agonisten |
Country Status (8)
Country | Link |
---|---|
US (3) | US5663292A (de) |
EP (2) | EP0797593A2 (de) |
JP (2) | JP2001527507A (de) |
AT (1) | ATE319742T1 (de) |
AU (2) | AU701699B2 (de) |
CA (2) | CA2206059A1 (de) |
DE (1) | DE69534852T2 (de) |
WO (2) | WO1996019499A2 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824771A (en) * | 1994-12-12 | 1998-10-20 | The Salk Institute For Biological Studies | Cyclic CRF agonists |
US5777073A (en) * | 1994-12-12 | 1998-07-07 | The Salk Institute For Biological Studies | Cyclic CRF antagonist peptides |
US6326463B1 (en) | 1994-12-12 | 2001-12-04 | The Salk Institute For Biological Studies | Cyclic CRF agonists |
US6323312B1 (en) | 1994-12-12 | 2001-11-27 | The Salk Institute For Biological Studies | Cyclic CRF antagonist peptides |
WO1997018238A2 (en) * | 1995-11-14 | 1997-05-22 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Crf analogs |
EP0866856A1 (de) * | 1995-11-14 | 1998-09-30 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Crf analoge und deren verwendung in photoaffinitätsmarkierung von crf-rezeptoren |
US5869450A (en) * | 1996-03-06 | 1999-02-09 | The Regents Of The University Of California | Anti-inflammatory compositions and method with corticotropin-releasing factor analogs |
US6846803B1 (en) * | 1998-07-24 | 2005-01-25 | Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. | Antagonists specific for the corticotropin-releasing factor receptor type 2 (CRFR2) |
US6319900B1 (en) | 1999-09-21 | 2001-11-20 | The Regents Of The University Of California | Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs |
AU1139301A (en) * | 1999-10-18 | 2001-04-30 | Solvay Pharmaceuticals B.V. | Peptides having corticotropin releasing factor (crf) antagonist activity |
EP1094072A1 (de) * | 1999-10-18 | 2001-04-25 | Duphar International Research B.V | Peptide mit Corticotropin-Freisetzende-Factor (CRF) antagonistischer Aktivität |
CA2416986A1 (en) * | 2000-07-19 | 2002-01-24 | Bristol-Myers Squibb Pharma Company | Crf2 ligands in combination therapy |
EP1319024A2 (de) * | 2000-09-22 | 2003-06-18 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Verfahren zur verbesserung der agonistischen bzw. antagonistischen eigenschaften von agonisten bzw. antagonisten des rezeptors von corticotropin-freisetzenden faktors (crfr) |
US6670140B2 (en) * | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
WO2003011823A2 (en) * | 2001-08-01 | 2003-02-13 | The Salk Institute For Biological Studies | Crfr1 selective ligands |
US7141546B1 (en) | 2001-08-01 | 2006-11-28 | The Salk Institute For Biologicial Studies | CRFR2 selective ligands |
US6936585B2 (en) * | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
US6849600B2 (en) * | 2002-03-25 | 2005-02-01 | The Regents Of The University Of California, Berkeley | Corticotropin-releasing hormone analogs |
US7815905B2 (en) * | 2006-01-27 | 2010-10-19 | Research Development Foundation | Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors |
US10166271B2 (en) * | 2006-06-21 | 2019-01-01 | The Regents Of The University Of California | Methods for promoting hair growth |
PL2076535T3 (pl) | 2006-10-16 | 2013-08-30 | Salk Inst Biological Studies | Antagoniści somatostatyny selektywni względem receptora (SSTR2) |
US8691761B2 (en) * | 2006-10-16 | 2014-04-08 | Jean E. F. Rivier | Somatostatin receptor 2 antagonists |
US20090035298A1 (en) * | 2007-04-23 | 2009-02-05 | Washington University In St. Louis | Methods to treat alzheimer's disease or other amyloid beta accumulation associated disorders |
CA2692039C (en) | 2007-06-13 | 2019-07-02 | Research Development Foundation | Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling |
RU2010114029A (ru) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Астрессин и бета-эндорфин для применения в качестве терапевтических средств |
WO2012088397A2 (en) | 2010-12-22 | 2012-06-28 | The Salk Institute For Biological Studies | Cyclic crf antagonist peptides |
WO2013063046A1 (en) | 2011-10-24 | 2013-05-02 | Research Development Foundation | Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors |
KR20180117636A (ko) | 2016-02-09 | 2018-10-29 | 씨디알디 벤쳐스 인코포레이티드 | 소마토스타틴 수용체 길항제 화합물 및 이의 이용 방법 |
GB201816621D0 (en) | 2018-10-12 | 2018-11-28 | Univ Leuven Kath | Prevention or treatment of adrenal insuffiency in critically ill patients |
DE102021111452B3 (de) | 2021-05-04 | 2022-07-28 | Positron Precision GmbH | Markierungsvorläufer und Radiotracer für neuroendokrine Theranostik |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4632780A (en) * | 1981-07-10 | 1986-12-30 | Seidah Nabil G | N-terminal fragment of human pro-opiomelanocortin and process therefor |
US5109111A (en) * | 1988-09-23 | 1992-04-28 | The Salk Institute For Biological Studies | CRF antagonists |
US5278146A (en) * | 1988-09-30 | 1994-01-11 | The Salk Institute For Biological Studies | CRF analogs |
US5064939A (en) * | 1990-02-06 | 1991-11-12 | The Salk Institute For Biological Studies | Cyclic gnrh antagonists |
US5245009A (en) * | 1990-03-23 | 1993-09-14 | The Salk Institute For Biological Studies | CRF antagonists |
US5235036A (en) * | 1991-05-31 | 1993-08-10 | The Salk Institute For Biological Studies | Crf analogs |
US5493006A (en) * | 1993-06-16 | 1996-02-20 | The Salk Institute For Biological Studies | Cyclic CRF analogs |
-
1994
- 1994-12-12 US US08/353,928 patent/US5663292A/en not_active Expired - Fee Related
-
1995
- 1995-11-10 US US08/556,578 patent/US5874227A/en not_active Expired - Lifetime
- 1995-12-08 AU AU45989/96A patent/AU701699B2/en not_active Ceased
- 1995-12-08 EP EP95944103A patent/EP0797593A2/de not_active Withdrawn
- 1995-12-08 JP JP51988896A patent/JP2001527507A/ja active Pending
- 1995-12-08 CA CA002206059A patent/CA2206059A1/en not_active Abandoned
- 1995-12-08 WO PCT/US1995/016261 patent/WO1996019499A2/en not_active Application Discontinuation
- 1995-12-12 JP JP51920896A patent/JP3765831B2/ja not_active Expired - Lifetime
- 1995-12-12 AU AU45145/96A patent/AU4514596A/en not_active Abandoned
- 1995-12-12 EP EP95943747A patent/EP0800532B1/de not_active Expired - Lifetime
- 1995-12-12 DE DE69534852T patent/DE69534852T2/de not_active Expired - Lifetime
- 1995-12-12 CA CA002207576A patent/CA2207576A1/en not_active Abandoned
- 1995-12-12 AT AT95943747T patent/ATE319742T1/de not_active IP Right Cessation
- 1995-12-12 WO PCT/US1995/016085 patent/WO1996018649A1/en active IP Right Grant
- 1995-12-19 US US08/575,148 patent/US5844074A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU4598996A (en) | 1996-07-10 |
JPH10511086A (ja) | 1998-10-27 |
DE69534852T2 (de) | 2006-09-21 |
CA2206059A1 (en) | 1996-06-27 |
WO1996018649A1 (en) | 1996-06-20 |
EP0797593A2 (de) | 1997-10-01 |
JP2001527507A (ja) | 2001-12-25 |
AU701699B2 (en) | 1999-02-04 |
WO1996019499A3 (en) | 1996-09-19 |
EP0800532B1 (de) | 2006-03-08 |
US5844074A (en) | 1998-12-01 |
DE69534852D1 (de) | 2006-05-04 |
CA2207576A1 (en) | 1996-06-20 |
JP3765831B2 (ja) | 2006-04-12 |
AU4514596A (en) | 1996-07-03 |
US5663292A (en) | 1997-09-02 |
WO1996019499A2 (en) | 1996-06-27 |
EP0800532A1 (de) | 1997-10-15 |
US5874227A (en) | 1999-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE319742T1 (de) | Verbesserte zyclische crf agonisten | |
IL123164A0 (en) | Meta-guanidine urea thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists | |
CY1108117T1 (el) | Φαρμακολογικως δραστικες ενωσεις με δυο ομοιοπολικως συνδεδεμενα δραστικα στοιχεια (αναστολεας διαυλων νατριου/αγωνιστης υποδοχεα ρ2υ2)για την αγωγη των βλεννογονιων επιφανειων | |
ATE199250T1 (de) | Sulfonamidocarbonylpyridin-2-carbonsäureamide und ihre verwendung als arzneimittel | |
GR3033661T3 (en) | Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo(c)azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace | |
ATE484521T1 (de) | Zyklische agonisten des crf | |
YU50502A (sh) | Postupak za prečišćavanje farmakološki aktivnih proteina pomoću katjonske izmenjivačke hromatografije | |
ES8501364A1 (es) | Un metodo para la preparacion de nuevos polipeptidos. | |
ES2104635T3 (es) | Nuevo peptido porcino con una actividad fisiologica (cnp-53). | |
PL311266A1 (en) | Application of indole derivatives as 5ht1 antagonists | |
DE69012901T2 (de) | Hämoregulierende Peptide. | |
TR200000697T2 (tr) | İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları. | |
BG103197A (en) | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptiees | |
AU671989B2 (en) | Treatment of tropical spastic paresis with peptide T | |
BG103306A (en) | Liquid allendronate compositions | |
MX9207429A (es) | Nuevo uso de derivados de aminoacido. | |
BG103502A (en) | Heterocyclic derivatives of carboxylic acids, their preparation and application as endothelial receptor antagonists | |
DE59301060D1 (de) | Substituierte Aminosäureamide. | |
ES2191014T3 (es) | Compuestos farmaceuticos de piridina. | |
ATE96450T1 (de) | Kleine peptide, die die bindung an t-4-rezeptoren inhibieren und als immunogene wirken. | |
DE69737561D1 (de) | Klonierte rezeptoren des glukagon-ähnlichen peptids-2 | |
FI971831A0 (fi) | Heterosyklillä substituoituja propeenihappojohdannaisia NMDA-antagonisteina | |
GB9604518D0 (en) | Novel compounds | |
MX9605048A (es) | Gonadotropinas con puentes de disulfuros no nativos. | |
IT1270613B (it) | Lattami biciclici come intermedi per la sintesi di peptidi biologicamente attivi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |